ARYA Sciences Acquisition Corp IV announced it has entered into subscription agreements for private placement of 20,150,000 common shares for $10 per share for gross proceeds of $201,500,000 on September 29, 2021. The transaction will include participation from Amicus Therapeutics, Inc. for $50,000,000, Perceptive Life Sciences Master Fund, Ltd., a fund managed by Perceptive Advisors LLC, Redmile Group, LLC and certain additional third party investors. The transaction has been approved by the board of directors of the company.

The par value of the shares to be issued is $0.0001 per share. The subscription agreements provide that company will grant the investors certain customary registration rights. Completion of the transaction, which is expected in the fourth quarter of 2021 or early 2022, is subject to approval of company's shareholders.

The company will incur expenses up to a maximum of $25,000,000.